RBC cuts Sartorius on limited near-term upside potential

Sartorius AG

09/01/2026 09:30

** RBC downgrades Sartorius SATG.DE to "sector-perform" from "outperform", citing a potentially limited near-term upside for the German lab equipment maker

** RBC expects a cautious outlook in FY results due to historical difficulties the company had in predicting recovery, adding that hiring activity at Sartorius nudged down in Q4, alongside smaller and larger peers

** RBC doubts management teams will be "overly bullish" on revenue growth forecasts for 2026

** RBC says that its most bullish scenario suggests 4% upside to consensus sales in 2026 and 9% in 2027, expecting this to be amplified with higher margins from operating leverage

** Shares in Sartorius and its French unit Stedim Biotech STDM.PA, which RBC also cuts to "sector-perform", are down 2.2% and 2.7%, respectively

(Reporting by Ozan Ergenay)

((ozan.ergenay@thomsonreuters.com))